Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00108-020-00850-9 http://scihub22266oqcxt.onion/10.1007/s00108-020-00850-9 32710161!7378303!32710161     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Internist+(Berl) 2020 ; 61 (8): 804-812 Nephropedia Template TP {{tp|p=32710161|t=2020. Therapie schwerer COVID-19-Verlaufe in der Intensivmedizin |pdf=|usr=}}{{32710161}} gab.com Text Therapie schwerer COVID-19-Verlaufe in der Intensivmedizin JO: Internist (Berl) http://www.kidney.de/pget.php?&tw=1&pmid=32710161 #FOAvip The pandemic triggered by coronavirus disease 2019 (COVID-19) has put intensive care medicine into the focus of public attention. The mortality of patients with the disease escalates, particularly at the moment when the treatment possibilities of intensive medical care end. In the routine intensive medical care practice, the challenges due to the special features of infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its treatment become obvious. These occur in the development and treatment of respiratory and multiorgan failure as well as the severe inflammatory syndrome. For these severe courses there is still only little evidence available as to which interventions are the most effective. In addition to the knowledge that can be gained from the rapid performance of clinical trials, the treatment is therefore based on analogies to other syndromes, such as sepsis and macrophage activation syndrome. Twit Text FOAVip Therapie schwerer COVID-19-Verlaufe in der Intensivmedizin ????Internist (Berl) http://www.kidney.de/pget.php?&tw=1&pmid=32710161 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32710161 #FOAvip English Wikipedia <ref>{{Cite pmid|32710161}}</ref> Therapie schwerer COVID-19-Verlaufe in der Intensivmedizin #MMPMID32710161 Wiesner O; Busch M; David S Internist (Berl) 2020[Aug]; 61 (8): 804-812 PMID32710161show ga The pandemic triggered by coronavirus disease 2019 (COVID-19) has put intensive care medicine into the focus of public attention. The mortality of patients with the disease escalates, particularly at the moment when the treatment possibilities of intensive medical care end. In the routine intensive medical care practice, the challenges due to the special features of infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its treatment become obvious. These occur in the development and treatment of respiratory and multiorgan failure as well as the severe inflammatory syndrome. For these severe courses there is still only little evidence available as to which interventions are the most effective. In addition to the knowledge that can be gained from the rapid performance of clinical trials, the treatment is therefore based on analogies to other syndromes, such as sepsis and macrophage activation syndrome. |*Critical Care[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*therapy[MESH]Therapie schwerer COVID-19-Verlaufe in der Intensivmedizin (epmc).pdf DeepDyve Pubget Overpricing